OrbiMed, a global healthcare investment firm, raised more than $4.3 billion in commitments for its latest private investment funds.
Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
The funds included OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV. These new vehicles enable OrbiMed to invest globally, from seed stage for start-ups incubated by OrbiMed through growth capital opportunities. The firm works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit and royalty-based financing. It focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services.
The company is led by its 21 partners, with a team exceeding 130 professionals that contribute diverse, complementary skills across company incubation, strategy, operations and finance. The firm’s professionals are based in New York City; London; San Francisco; Shanghai; Hong Kong; Mumbai, India; Herzliya, Israel; and other key global markets.
FinSMEs
24/10/2023